BioSpace News Archive

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics Inc.

Proteintech Genomics, a subsidiary of Proteintech Group, Inc., and a provider of multiomic solutions for single-cell and spatial analysis, announced the launch of the MultiPro™ Human Fixed Cell Immune Profiling Antibody Cocktail.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R) Revive Diagnostics Inc., today announced that it has entered into a license agreement with Lawson Health Research Institute for the worldwide exclusive rights to novel blood biomarkers that characterize long COVID.

Eyenovia, Inc. announced that the Company will release financial results for the third quarter ended September 30, 2023 on Monday, November 13, 2023, after the markets close.

Mesa Laboratories, Inc., a global leader in the design and manufacturing of life science tools and critical quality control solutions, announced results for its second fiscal quarter ended September 30, 2023.

Portage Biotech Inc. today announced the presentations of updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) engager for patients with NSCLC and advanced melanoma, and its ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 (A2A inhibitor) and PORT-7 (A2B inhibitor) in multiple solid tumors at SITC.

Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in November.

Soleno Therapeutics, Inc. today announced publication of one-year results from the Phase 3 DESTINY PWS study and the open-label extension period of Study C602 evaluating investigational, once-daily DCCR (Diazoxide Choline) Extended-Release tablets for patients with Prader-Willi syndrome (PWS).

Indaptus Therapeutics, Inc. announces interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20.

Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fourth quarter ended July 31, 2023, and the fiscal year ended July 31, 2023, and also provided a general business update.